该股主要指标及行业内排名如下： 证券之星消息，截至2025年12月30日收盘，蓝帆医疗(002382)报收于5.51元，下跌1.25%，换手率 0.67%，成交量6.73万手，成交额3729.43万元。 12月30日的资金流向数据方面，主力资金净流入91.51万元，占总成交额2.45%，游资资金净流入97.56 万元，占总成交额2.62%，散户资金净流出189.07万元，占总成交额5.07%。 近5日资金流向一览见下表： 资金流向名词解释：指通过价格变化反推资金流向。股价处于上升状态时主动性买单形成的成交额是推 动股价上涨的力量，这部分成交额被定义为资金流入，股价处于下跌状态时主动性卖单产生的的成交额 是推动股价下跌的力量，这部分成交额被定义为资金流出。当天两者的差额即是当天两种力量相抵之后 剩下的推动股价上升的净力。通过逐笔交易单成交金额计算主力资金流向、游资资金流向和散户资金流 向。 注：主力资金为特大单成交，游资为大单成交，散户为中小单成交 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 蓝帆医疗2025年三季报显示，前三季度 ...

Core Viewpoint - Bluefan Medical (002382) has experienced a decline in stock price and financial performance, indicating potential challenges in the medical device industry [1][3]. Group 1: Stock Performance - As of December 4, 2025, Bluefan Medical's stock closed at 5.46 yuan, down 2.5% with a turnover rate of 0.86% and a trading volume of 85,600 hands, amounting to a total transaction value of 47.07 million yuan [1]. - The net outflow of main funds on December 4 was 6.0374 million yuan, accounting for 12.83% of the total transaction value, while retail investors saw a net inflow of 3.9286 million yuan, representing 8.35% of the total [1]. Group 2: Recent Fund Flow - Over the past five days, the stock has shown a consistent trend of net outflows from main funds, with the highest outflow recorded on December 2 at 12.9393 million yuan, which was 32.24% of the total transaction value [2]. - The net inflow from retail investors peaked on December 2 at 8.4658 million yuan, which was 21.09% of the total transaction value for that day [2]. Group 3: Financial Performance - For the first three quarters of 2025, Bluefan Medical reported a main revenue of 4.182 billion yuan, a year-on-year decrease of 10.15%, and a net profit attributable to shareholders of -286 million yuan, down 30.09% [3]. - The company's gross profit margin stands at 13.66%, significantly lower than the industry average of 51.22%, indicating a challenging competitive position [3]. - The company's total market capitalization is 5.499 billion yuan, with a net asset value of 9.707 billion yuan, ranking 63rd in the industry [3].

Core Viewpoint - Bluefan Medical (002382) has experienced a decline in stock price and financial performance, indicating potential challenges in the medical device industry [1][3]. Financial Performance - As of December 3, 2025, Bluefan Medical's stock closed at 5.6 yuan, down 0.71% with a trading volume of 69,300 shares and a turnover of 38.97 million yuan [1]. - The company reported a total revenue of 4.182 billion yuan for the first three quarters of 2025, a year-on-year decrease of 10.15% [3]. - The net profit attributable to shareholders was -286 million yuan, a decline of 30.09% year-on-year [3]. - The third quarter alone saw a revenue of 1.401 billion yuan, down 15.02% year-on-year, and a net profit of -151 million yuan, a staggering decline of 153.64% [3]. Market Position - Bluefan Medical's total market capitalization is 5.64 billion yuan, significantly lower than the industry average of 11.01 billion yuan, ranking 63rd out of 124 in the medical device sector [3]. - The company's net asset value stands at 9.707 billion yuan, which is above the industry average of 3.893 billion yuan, ranking 7th [3]. - The price-to-earnings ratio is -14.79, while the industry average is 60.46, indicating a negative earnings situation [3]. - The gross margin is 13.66%, significantly lower than the industry average of 51.22%, ranking 121st [3]. Capital Flow - On December 3, 2025, the net outflow of main funds was 3.1814 million yuan, accounting for 8.16% of the total turnover [1][2]. - Retail investors showed a net inflow of 5.2753 million yuan, representing 13.54% of the total turnover on the same day [1][2]. - Over the past five days, the trend shows a consistent outflow of main funds, with the highest outflow recorded on December 2 at 12.9393 million yuan [2].

Core Viewpoint - Bluefan Medical (002382) has shown a decline in stock price and financial performance, with significant net losses reported in recent quarters, indicating potential challenges in the medical device industry [1][3]. Financial Performance - As of November 28, 2025, Bluefan Medical's stock closed at 5.73 yuan, down 0.35%, with a trading volume of 76,600 hands and a transaction value of 43.58 million yuan [1]. - In the third quarter of 2025, the company reported a main revenue of 14.01 billion yuan, a year-on-year decrease of 15.02%, and a net profit attributable to shareholders of -1.51 billion yuan, a decline of 153.64% [3]. - For the first three quarters of 2025, the company's main revenue was 41.82 billion yuan, down 10.15%, with a net profit of -2.86 billion yuan, a decrease of 30.09% [3]. Market Position - Bluefan Medical's total market value is 5.771 billion yuan, significantly lower than the industry average of 11.144 billion yuan, ranking 62 out of 124 in the medical device sector [3]. - The company's net asset stands at 9.707 billion yuan, ranking 7 in the industry, while its net profit is the lowest in the sector at -2.86 billion yuan, ranking 124 [3]. - The company's price-to-earnings ratio is -15.14, and its price-to-book ratio is 0.75, indicating a low valuation compared to the industry average [3]. Capital Flow - On November 28, 2025, the net inflow of main funds was 711,400 yuan, accounting for 1.63% of the total transaction value, while retail investors saw a net outflow of 2.1339 million yuan, representing 4.9% of the total [1][2]. - Over the past five days, the stock has experienced fluctuating capital flows, with significant net outflows from retail investors on multiple days [2].

Core Viewpoint - Bluefan Medical (002382) has shown a mixed performance in terms of stock price and financial metrics, with a notable decline in revenue and profit margins in recent quarters [1][3]. Financial Performance - As of November 12, 2025, Bluefan Medical's stock closed at 5.82 yuan, up 0.87% with a trading volume of 139,000 shares and a transaction value of 81.01 million yuan [1]. - The company reported a total revenue of 4.182 billion yuan for the first three quarters of 2025, a year-on-year decrease of 10.15% [3]. - The net profit attributable to shareholders was -286 million yuan, down 30.09% year-on-year, with a net profit margin of -7.24% [3]. - The third quarter alone saw a revenue of 1.401 billion yuan, a decline of 15.02% year-on-year, and a net profit of -151 million yuan, a staggering drop of 153.64% [3]. Market Position - Bluefan Medical's total market capitalization is 5.862 billion yuan, ranking 62nd in the medical device industry, which has an average market cap of 11.669 billion yuan [3]. - The company has a price-to-earnings ratio of -15.37, significantly lower than the industry average of 60.71, indicating challenges in profitability [3]. - The company's gross margin stands at 13.66%, compared to the industry average of 51.22%, placing it at 121st in the industry ranking [3]. Capital Flow - On November 12, 2025, the net outflow of main funds was 4.1047 million yuan, accounting for 5.07% of the total transaction value, while retail investors saw a net inflow of 2.8734 million yuan, representing 3.55% of the total [1][2]. - Over the past five days, the stock has experienced fluctuations in capital flow, with notable net inflows and outflows from different investor categories [2].

Core Viewpoint - Bluefan Medical (002382) has shown a slight increase in stock price but continues to face significant financial challenges, with declining revenues and profits in recent quarters [1][3]. Financial Performance - As of November 3, 2025, Bluefan Medical's stock closed at 5.51 yuan, up 0.18% with a trading volume of 74,000 shares and a turnover of 40.68 million yuan [1]. - In the third quarter of 2025, the company reported a main revenue of 14.01 billion yuan, a year-on-year decrease of 15.02%, and a net profit attributable to shareholders of -1.51 billion yuan, a decline of 153.64% [3]. - For the first three quarters of 2025, the total revenue was 41.82 billion yuan, down 10.15%, with a net profit of -2.86 billion yuan, a decrease of 30.09% [3]. Market Position - Bluefan Medical's total market capitalization is 5.549 billion yuan, ranking 64th in the medical device industry, which has an average market cap of 11.617 billion yuan [3]. - The company's net asset value stands at 9.707 billion yuan, significantly higher than the industry average of 3.893 billion yuan, ranking 7th [3]. - The company has a price-to-earnings ratio of -14.55, while the industry average is 63.42, indicating a challenging profitability outlook [3]. Profitability Metrics - Bluefan Medical's gross margin is 13.66%, compared to the industry average of 51.22%, ranking 121st in the industry [3]. - The net profit margin is -7.24%, significantly lower than the industry average of 9.57%, ranking 109th [3]. - The return on equity (ROE) is -3.56%, while the industry average is 0.15%, indicating poor financial performance relative to peers [3]. Capital Flow Analysis - On November 3, 2025, the net outflow of main funds was 2.3752 million yuan, accounting for 5.84% of the total turnover, while retail investors saw a net inflow of 1.4859 million yuan, representing 3.65% of the total turnover [1][2]. - Over the past five days, the stock has experienced fluctuating capital flows, with significant net outflows from main funds on several days, indicating a lack of confidence from institutional investors [2].

Core Insights - Bluefan Medical (002382) reported a closing price of 5.62 yuan on October 27, 2025, with a decrease of 0.35% and a trading volume of 76,700 hands, resulting in a transaction amount of 43.11 million yuan [1] Fund Flow Analysis - On October 27, 2025, the net outflow of main funds was 6.6866 million yuan, accounting for 15.51% of the total transaction amount, while retail investors saw a net inflow of 3.5591 million yuan, representing 8.26% of the total transaction amount [1][2] - Over the past five days, the main funds experienced consistent outflows, with the largest outflow recorded on October 22 at 2.8389 million yuan, while retail investors consistently showed net inflows [2] Company Performance Metrics - Bluefan Medical's total market value is 5.66 billion yuan, significantly lower than the industry average of 11.652 billion yuan, ranking 62 out of 124 in the medical device industry [3] - The company reported a net profit of -135 million yuan, with a year-on-year decline in main revenue of 7.49% to 2.781 billion yuan [3] - The gross profit margin stands at 14.34%, which is considerably lower than the industry average of 51.35%, ranking 120 out of 124 [3] - The company's debt ratio is 41.19%, with financial expenses amounting to 69.4351 million yuan [3]

Core Viewpoint - Bluefan Medical (002382) has shown a mixed performance in recent trading, with a slight increase in stock price but a significant decline in financial metrics, indicating potential challenges ahead for the company [1][3]. Financial Performance - As of October 20, 2025, Bluefan Medical's stock closed at 5.68 yuan, up 3.27% with a trading volume of 156,500 shares and a total transaction value of 88.86 million yuan [1]. - The company reported a main operating revenue of 2.781 billion yuan for the first half of 2025, a year-on-year decrease of 7.49% [3]. - The net profit attributable to shareholders was -135 million yuan, which represents a year-on-year increase of 15.88% [3]. - The second quarter of 2025 saw a significant decline in performance, with a single-quarter main operating revenue of 1.303 billion yuan, down 16.0% year-on-year, and a net profit of -212 million yuan, a decrease of 245.53% [3]. Market Position and Ratios - Bluefan Medical's total market capitalization is 5.721 billion yuan, ranking 62nd in the medical device industry, which has an average market cap of 11.662 billion yuan [3]. - The company has a price-to-earnings ratio (P/E) of -21.22, compared to the industry average of 65.67, indicating a challenging earnings environment [3]. - The company's price-to-book ratio (P/B) stands at 0.73, significantly lower than the industry average of 3.77, suggesting undervaluation relative to its book value [3]. - Bluefan Medical's gross margin is 14.34%, which is considerably lower than the industry average of 51.83%, reflecting operational inefficiencies [3]. Capital Flow Analysis - On October 20, 2025, the net inflow of main funds was 9.7742 million yuan, accounting for 11.0% of the total transaction value, while retail investors saw a net outflow of 14.9712 million yuan, representing 16.85% of the total [1][2]. - Over the past five days, the stock has experienced fluctuations in capital flow, with notable net inflows and outflows from both institutional and retail investors [2].

Core Viewpoint - As of October 14, 2025, BluFan Medical (002382) closed at 5.6 yuan, marking a 1.45% increase, with a trading volume of 92,800 hands and a total transaction amount of 51.79 million yuan [1] Group 1: Financial Performance - BluFan Medical reported a total market value of 56.4 billion yuan, with a net asset of 99.05 billion yuan, ranking 62nd in the medical device industry [3] - The company experienced a net profit of -1.35 billion yuan, which is a 15.88% increase year-on-year, while its main revenue decreased by 7.49% to 2.781 billion yuan [3] - The gross profit margin stood at 14.34%, significantly lower than the industry average of 51.85%, ranking 120th in the industry [3] Group 2: Recent Trading Activity - On October 14, 2025, the main funds saw a net inflow of 2.785 million yuan, accounting for 5.38% of the total transaction amount, while retail investors experienced a net outflow of 729,700 yuan, representing 1.41% of the total [1][2] - Over the past five days, the stock has seen fluctuating fund flows, with notable net outflows from retail and speculative funds on several days [2] Group 3: Key Financial Ratios - The price-to-earnings ratio (P/E) is -20.92, while the price-to-book ratio (P/B) is 0.72, indicating a relatively low valuation compared to the industry average [3] - The company's return on equity (ROE) is -1.66%, which is below the industry average of 1.8% [3]

Core Viewpoint - Bluefan Medical (002382) has experienced a decline in stock price and financial performance, with significant net outflows from major funds, indicating potential challenges in the market [1][2]. Financial Performance - As of the latest report, Bluefan Medical's total revenue for the first half of 2025 was 2.781 billion yuan, a year-on-year decrease of 7.49% [2]. - The company reported a net profit of -135 million yuan, which is an increase of 15.88% year-on-year, indicating worsening profitability despite the increase in losses [2]. - The second quarter of 2025 saw a single-quarter revenue of 1.303 billion yuan, down 16.0% year-on-year, and a net profit of -212 million yuan, a significant decline of 245.53% year-on-year [2]. Market Position - Bluefan Medical's total market capitalization is 5.64 billion yuan, significantly lower than the industry average of 12.177 billion yuan, ranking 63rd out of 123 companies in the medical device sector [2]. - The company's net assets stand at 9.905 billion yuan, which is above the industry average of 3.889 billion yuan, ranking 7th in the industry [2]. - The price-to-earnings ratio (P/E) is -20.92, compared to the industry average of 67.16, indicating a lack of profitability [2]. Profitability Metrics - Bluefan Medical's gross margin is 14.34%, significantly lower than the industry average of 51.85%, ranking 120th in the industry [2]. - The net profit margin is -5.14%, compared to the industry average of 10.39%, ranking 106th [2]. - Return on equity (ROE) is -1.66%, while the industry average is 1.8%, ranking 112th [2]. Fund Flow Analysis - On October 9, 2025, Bluefan Medical's stock closed at 5.6 yuan, down 0.18%, with a turnover rate of 0.79% and a trading volume of 79,200 hands, amounting to a total transaction value of 44.1552 million yuan [1]. - The net outflow of major funds on the same day was 8.566 million yuan, accounting for 19.4% of the total transaction value, while retail investors saw a net inflow of 4.7937 million yuan, representing 10.86% of the total [1].